Results 41 to 50 of about 4,267 (203)
Is There Clinical Value in Measuring suPAR Levels in FSGS? [PDF]
Clinical Journal of the American Society of Nephrology, 2013 FSGS is a podocyte-derived glomerular disease characterized by marked proteinuria, often coupled with steroid resistance, hypertension, and high probability for progression to renal failure. It is a heterogeneous disorder that can present as a primary disorder of unknown etiology.
Sanja, Sever +3 more
openaire +2 more sources
JCI Insight, 2023 Acute kidney injury (AKI) secondary to sepsis results in poor outcomes and conventional kidney function indicators lack diagnostic value. Soluble urokinase plasminogen activator receptor (suPAR) is an innate immune–derived molecule implicated in ...
Christian Nusshag +23 more
doaj +1 more source
Frontiers in Immunology, 2021 Systemic chronic inflammation (SCI) is persistent, health-damaging, low-grade inflammation that plays a major role in immunosenescence and in development and progression of many diseases.
Line Jee Hartmann Rasmussen +3 more
doaj +1 more source
Plasma Soluble Urokinase Plasminogen Activator Receptor in Children with Urinary Tract Infection
Biomarker Insights, 2011 Objective In this prospective study we investigated the role of plasma levels of soluble urokinase plasminogen activator receptor (suPAR) in children with urinary tract infection.
Per Wittenhagen +7 more
doaj +1 more source
Evaluation of the relationship between KIM-1 and suPAR level in COVID-19 patients and a different perspective on suPAR [PDF]
Acute critical care, 2021 Objective: COVID-19 is one of the most important health problems concerning the last century and our knowledge of the disease is still limited. In our study, we aimed to compare serum-soluble urokinase plasminogen activator receptor (suPAR) and kidney injury molecule-1 (KIM-1) level with clinical course in COVID-19 patients. Methods: Our study included
Buğra Kerget +5 more
openaire +1 more source
Soluble Urokinase Receptor Levels Are Correlated with Focal Segmental Glomerulosclerosis Lesions in IgA Nephropathy: A Cohort Study from China. [PDF]
PLoS ONE, 2015 Soluble urokinase receptor (suPAR) may be involved in the pathological mechanisms of focal segmental glomerulosclerosis (FSGS) changes. However, it remains unclear whether suPAR is correlated with the FSGS-like lesions in IgA nephropathy (IgAN).We ...
Shui-Ming Guo +13 more
doaj +1 more source
Gastroenterology Research and Practice, 2019 Aims. Soluble urokinase plasminogen activator receptor (suPAR) reflects the immune activation in circumstances of inflammation and infection. It has been considered as a risk biomarker associated with poor outcome in various low-grade inflammation and ...
Zuxiong Huang +8 more
doaj +1 more source
Asian Journal of Medical Sciences, 2021 Background: Soluble urokinase plasminogen receptor (suPAR) is a protein in the blood that has been described to reflect the severity status of systemic inflammation.
Ioannis Griveas +4 more
doaj +1 more source
Biomarker Insights, 2017 Inflammation has been proposed to play a role in the generation of depressive symptoms. Previously, we demonstrated that patients with major depressive disorder (MDD) have increased plasma levels of the soluble form of the urokinase receptor (suPAR), a ...
Anna Gustafsson +5 more
doaj +1 more source
The Journal of Clinical Investigation, 2022 Atherosclerosis contributes to the majority of deaths related to cardiovascular disease (CVD). Recently, the nonspecific inflammatory biomarker soluble urokinase plasminogen activator receptor (suPAR) has shown prognostic value in patients with CVD ...
Traci T. Goodchild +2 more
doaj +1 more source